Discriminating Between Essential Thrombocythemia and Masked Polycythemia Vera in JAK2 Mutated Patients

Overview

Journal Am J Hematol

Specialty Hematology

Date 2014 Feb 19

PMID 24535932

Citations 24

Authors

Tiziano Barbui

Jurgen Thiele

Alessandra Carobbio

Paola Guglielmelli

Alessandro Rambaldi

Alessandro M Vannucchi

Ayalew Tefferi

Affiliations

Soon will be listed here.

Abstract

In patients not meeting the required hematocrit (HCT) or hemoglobin (Hb) thresholds according to BCSH and the WHO diagnostic criteria, the diagnosis of masked polycythemia vera (mPV) has been proposed. A comparison of HCT or Hb values with the expression of JAK2V617F, JAK2 exon 12, and CALR mutations in strictly WHO-defined 257 overt PV and 140 mPV (59 mPV according to BCSH) and 397 patients with essential thrombocythemia (ET) was performed. Hb and HCT thresholds of mPV patients were significantly higher than JAK2V617F ET (P < 0.0001). The best cut-off for Hb to discriminate JAK2-mutated ET from PV was 16.5 g/dL for males and 16.0 g/dL for females. For HCT, this was 49% in males and 48% in females. The proportion of patients correctly classified as ET or PV when regarding Hb or HCT levels was 95% in males and 93% in females and 94% in both males and females, respectively.

Citing Articles

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

Thiele J, Kvasnicka H, Gianelli U, Arber D, Tefferi A, Vannucchi A Blood Cancer J. 2025; 15(1):31.

PMID: 40038244 PMC: 11880409. DOI: 10.1038/s41408-025-01235-7.

Updated threshold, renewed problems: should the diagnostic criteria of polycythemia vera be reconsidered? A retrospective cross-sectional cohort study.

Ucan A, Okay Ozgeyik M Rev Assoc Med Bras (1992). 2024; 70(1):e20230497.

PMID: 38511749 PMC: 10941872. DOI: 10.1590/1806-9282.20230497.

The Combination of Allele Burden and Expression can Be Helpful in Distinguishing the Subtype of MPN Patients.

Wu S, Luo P, Rouzi T, Yu Y, Xiong B, Wang Y Cancer Control. 2023; 30:10732748231163648.

PMID: 36895113 PMC: 10009047. DOI: 10.1177/10732748231163648.

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.

Pizzi M, Croci G, Ruggeri M, Tabano S, Dei Tos A, Sabattini E Cancers (Basel). 2021; 13(22).

PMID: 34830822 PMC: 8616346. DOI: 10.3390/cancers13225666.

Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.

Sabattini E, Pizzi M, Agostinelli C, Bertuzzi C, Sagramoso Sacchetti C, Palandri F Cancers (Basel). 2021; 13(21).

PMID: 34771693 PMC: 8583143. DOI: 10.3390/cancers13215531.